Summary
Clinical trials (CT) take an average of 8 years and $100M to complete and is a key component in drug development. Relevant to this proposal, some of the reasons that cause CTs to have high costs and lengthy time frames for Study Sponsors are ineffective monitoring, poor quality control measures, poor data management and lack of reporting tools. Among all phases, on average, these challenges amount approximately the 45-50% of the costs. Furthermore, traditional methods for evaluating the evolution of the patient’s symptoms produce data that is episodic, subjective and scarce, meaning that patients, clinicians, and other stakeholders do not get the needed evidence for making real-world decisions.
We propose humanITcare, a disruptive Internet of Things (IoT) platform that provides Real World Data (RWD) & Real-World Evidence (RWE) which is innovative because provides a passive 24/7 remote monitoring of patient’s symptoms in CTs, validated in a clinical study with 60 participants in Hospital Clinic of Barcelona.
Patients and clinical researchers are the final users with whom we have extensively worked on locally and at a European level in product validation and market fit. In the first internationalization year, we plan to go to strategic EU countries (Belgium, Germany and Sweden).
We are a multidisciplinary team, including senior physicians, data scientists, software engineers as well as business and health experts. We have been awarded thrice from EIT Health. Our ambition is to be the best company for remotely monitoring the health of patients or the overall population using their own devices or disease-specific devices. With the grant and the coaching of the SME phase I, we intend to perform 1) market study; 2) regulatory analysis; 3) business plan. As part of our ambition, in 4 years, we will work towards entering the clinical market too with the aim to improve patients’ health outcomes by providing a better follow-up.
We propose humanITcare, a disruptive Internet of Things (IoT) platform that provides Real World Data (RWD) & Real-World Evidence (RWE) which is innovative because provides a passive 24/7 remote monitoring of patient’s symptoms in CTs, validated in a clinical study with 60 participants in Hospital Clinic of Barcelona.
Patients and clinical researchers are the final users with whom we have extensively worked on locally and at a European level in product validation and market fit. In the first internationalization year, we plan to go to strategic EU countries (Belgium, Germany and Sweden).
We are a multidisciplinary team, including senior physicians, data scientists, software engineers as well as business and health experts. We have been awarded thrice from EIT Health. Our ambition is to be the best company for remotely monitoring the health of patients or the overall population using their own devices or disease-specific devices. With the grant and the coaching of the SME phase I, we intend to perform 1) market study; 2) regulatory analysis; 3) business plan. As part of our ambition, in 4 years, we will work towards entering the clinical market too with the aim to improve patients’ health outcomes by providing a better follow-up.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/885173 |
| Start date: | 01-12-2019 |
| End date: | 31-05-2020 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Clinical trials (CT) take an average of 8 years and $100M to complete and is a key component in drug development. Relevant to this proposal, some of the reasons that cause CTs to have high costs and lengthy time frames for Study Sponsors are ineffective monitoring, poor quality control measures, poor data management and lack of reporting tools. Among all phases, on average, these challenges amount approximately the 45-50% of the costs. Furthermore, traditional methods for evaluating the evolution of the patient’s symptoms produce data that is episodic, subjective and scarce, meaning that patients, clinicians, and other stakeholders do not get the needed evidence for making real-world decisions.We propose humanITcare, a disruptive Internet of Things (IoT) platform that provides Real World Data (RWD) & Real-World Evidence (RWE) which is innovative because provides a passive 24/7 remote monitoring of patient’s symptoms in CTs, validated in a clinical study with 60 participants in Hospital Clinic of Barcelona.
Patients and clinical researchers are the final users with whom we have extensively worked on locally and at a European level in product validation and market fit. In the first internationalization year, we plan to go to strategic EU countries (Belgium, Germany and Sweden).
We are a multidisciplinary team, including senior physicians, data scientists, software engineers as well as business and health experts. We have been awarded thrice from EIT Health. Our ambition is to be the best company for remotely monitoring the health of patients or the overall population using their own devices or disease-specific devices. With the grant and the coaching of the SME phase I, we intend to perform 1) market study; 2) regulatory analysis; 3) business plan. As part of our ambition, in 4 years, we will work towards entering the clinical market too with the aim to improve patients’ health outcomes by providing a better follow-up.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
